Meeting
2023 ASCO Annual Meeting
Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.
Authors
Hannah Majeski
San Diego, CA
Hannah Majeski , Akinori Okano , Angela Pasis , Casey Carlson , Arvind Shakya , Shenlin Huang , Aparajita Hoskote Chourasia , Leah M. Fung , Qiao Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1083)
DOI
10.1200/JCO.2023.41.16_suppl.1083
Abstract #
1083
Poster Bd #
304
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
First Author: Ayca Gucalp
Poster
2022 ASCO Annual Meeting
CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.
First Author: Laura Sabina Lapuchesky
Poster
2019 ASCO Annual Meeting
NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.
First Author: Bo Zhang
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine